The potential of artificial intelligence and enabling technology to shorten drug development timelines and enhance productivity.
In this article by The Medicine Maker, Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, and other experts highlight the optimism around Ai's potential to revolutionize pharma over the next decade and improve clinical trial processes.
Clinical Success Through Continuous Refinement – with Andrew Lewis, Chief Scientific Officer, Quotient Sciences: "It has been just over a year since we saw the first fully generative Ai-created drug enter human trials (Insilico Medicine’s INS018_055) and the excitement about AI and its potential has far from waned."
“The continual linkages that we can build between AI and other in silico tools will lead to tremendous improvements in productivity across our industry, advancing the next frontier of medicines.” commented Dr. Lewis.
Continue reading the full article on The Medicine Maker
“The continual linkages that we can build between AI and other in silico tools will lead to tremendous improvements in productivity across our industry, advancing the next frontier of medicines.”
Dr. Andrew Lewis